









MNKD Products & Pipeline

 Endocrine

 Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
Afrezza® (insulin human) Inhalation Powder	T1 and T2 diabetes mellitus (adults)	 Marketed / Phase 4 INHALE-3 (Complete) International Expansion: Brazil (Biommm); India (Cipla): In Process				
Pediatric Afrezza® (insulin human) Inhalation Powder	Indication Expansion: T1 and T2 diabetes mellitus (pediatrics)	 Phase 3 / INHALE-1 (Complete)				
V-Go® All-in-One Insulin Delivery Patch	management of diabetes mellitus in persons requiring insulin (adults)	 Marketed				
Tyvaso DPI® (marketed by United Therapeutics)	pulmonary arterial hypertension / pulmonary hypertension associated with interstitial lung disease	 Marketed				
	Idiopathic pulmonary fibrosis	 UT: Phase 3 TETON 1 & 2				
Clofazimine Inhalation Suspension (MNKD-101)	nontuberculous mycobacterial lung disease	 Phase 3 ICoN-1 (On Track)				
Nintedanib DPI (MNKD-201)	idiopathic pulmonary fibrosis	 Phase 1 (Completed)				
Dornase Alfa (MNKD-301)	cystic fibrosis	 Preclinical				